Am J Transplant, Volume 22, Suppl 3 Archives - Page 10 of 190 - ATC Abstracts

2022 American Transplant Congress
PCR-Enhanced Performance Characteristics of TruGraf Gene Expression Profile in Kidney Transplant
P. West-Thielke¹, J. Fleming¹, C. Miller¹, N. Grund¹, A. Sutton¹, R. Sinha², M. Miller², S. Kleiboeker², J. Weems³
¹Transplant Genomics, Inc., Framingham, MA, ²Eurofins-Viracor, Lees Summit, MO, ³Transplant Genomics, Inc., Lees Summit, MO
*Purpose: The aim of this study was to perform clinical validation of TruGraf GEP using PCR methodology, as compared to the previously used microarray methodology,…
2022 American Transplant Congress
Technology-Driven Performance Improvement of a Biomarker Panel in Kidney Transplant: OmniGraf
P. West-Thielke, C. Miller, N. Grund, A. Sutton, R. Sinha, M. Miller, S. Kleiboeker, J. Weems
Eurofins, Framingham, MA
*Purpose: Analyze the impact of the transition from TruGraf microarray to TruGraf PCR on the complementary performance characteristics of TruGraf plus TRAC (OmniGraf).*Methods: Development of…
2022 American Transplant Congress
A Novel Mismatch That Modulates the Innate Alloresponse Risk Stratifies Renal Transplant Patients
H. Dai, K. Abou Daya, M. Oberbarnscheidt, R. Mehta, C. Macedo, D. Metes, Q. Xu, A. Zeevi, P. Randhawa, F. Lakkis, A. Cherukuri
Thomas E. Starzl Transplantation Institute, UPMC, Pittsburgh, PA
*Purpose: Donor polymorphism in the gene encoding signal regulatory protein alpha (SIRPα) is a key modulator of the recipient’s innate alloresponse. Here, we investigated the…
2022 American Transplant Congress
A Single Center Analysis of Organ Offers and Workload for Liver and Kidney Allocation
V. Reddy, T. Ma, R. Ruiz, H. Fernandez, J. Bayer, N. Onaca, E. Martinez, A. Gupta, S. Lee, G. J. McKenna, G. Testa, A. Wall
Baylor University Medical Center, Dallas, TX
*Purpose: UNOS/OPTN transitioned to Acuity Circles allocation for kidneys and livers which has increased the complexity of the network of organ procurement organizations (OPOs) and…
2022 American Transplant Congress
HLA-II Subclasses Behave Differently Between Themselves and Between Humans: Cues to Understand Alloreactivity
S. Beland, O. Desy, M. Marcoux, M. Thivierge, J. Desgagnes, S. A. De Serres
Transplantation Unit, Renal Division, University Health Center of Quebec, Faculty of Medicine, Universite Laval, Quebec, QC, Canada
*Purpose: De novo anti-HLA-II DSAs (dnDSA) are associated with antibody-mediated rejection. However, some patients with anti-HLA-II DSAs will not develop rejection, suggesting that the development…
2022 American Transplant Congress
Pegloticase Use in Renal Transplant Recipients with Gout: Findings from an Insurance Claims Database Study
C. A. Shadur¹, B. Marder², C. Vesel², B. LaMoreaux²
¹Iowa Kidney Physicians, Des Moines, IA, ²Horizon Therapeutics plc, Deerfield, IL
*Purpose: Kidney transplant (KT) recipients have high gout incidence due to reduced eGFR and medication use associated with hyperuricemia.1 Oral urate-lowering therapies in KT patients…
2022 American Transplant Congress
Sodium-Glucose Cotransporter 2 Inhibitors to Treat Diabetes Mellitus After Kidney Transplant
H. M. Brokmeier¹, S. B. Leung¹, A. Kukla², K. C. Mara³, P. Shah⁴, Y. Kudva⁴, G. K. Mour⁵, H. M. Wadei⁶, J. M. Hill⁷, M. D. Stegall⁸, A. Lemke¹
¹Pharmacy, Mayo Clinic, Rochester, MN, ²Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, ⁵Nephrology Transplant, Mayo Clinic, Phoenix, AZ, ⁶Nephrology, Mayo Clinic, Jacksonville, FL, ⁷Transplant, Mayo Clinic, Rochester, MN, ⁸Division of Transplant Surgery, Mayo Clinic, Rochester, MN
*Purpose: This study describes experience prescribing sodium-glucose cotransport 2 inhibitors (SGLT2i) after kidney transplant to evaluate safety and effectiveness.*Methods: This is a retrospective, institutional review…
2022 American Transplant Congress
Sirolimus Regimens After Kidney Transplantation: Role of Pre-Transplant Risk Factors in Modifying the Risk of Mortality in Adult Recipients
A. Santos¹, H. Ibrahim¹, M. A. Leghrouz¹, X. Wen²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kinston, RI
*Purpose: We aimed to investigate the role of risk factors in modifying the association of sirolimus with mortality in kidney transplant (KT) recipients (KTRs).*Methods: Using…
2022 American Transplant Congress
Coordinated, Multimodal Care After Kidney Transplantation Improves Graft Survival and Cardiovascular Risks – Results of the Kidney Transplantation 360°- Study (ktx360°)
L. Pape¹, M. DeZwaan², V. Kliem³, H. Nolting⁴, J. Wolff⁴, U. Tegtbur⁵, M. Schiffer⁶
¹Pediatrics II, University Hospital of Essen, Essen, Germany, ²Pediatrics II, Hannover Medical School, Hannover, Germany, ³Nephrologic Center Hannoversch Münden, Hannoversch Münden, Germany, ⁴IGES Insititue, Berlin, Germany, ⁵Hannover Medical School, Hannover, Germany, ⁶University Hospital of Erlangen, Erlangen, Germany
*Purpose: Cardiovascular events and reduced graft survival due to non-adherence are the most important reasons for morbidity and mortality after KTx. Outpatient care in Germany…
2022 American Transplant Congress
Bone Fractures Are Not Increased in Older Prior Living Kidney Donors
H. Amer¹, H. Maradit Kremers¹, D. Larson¹, I. Zaniletti¹, W. K. Kremers¹, A. Matas², B. Kasiske³, S. Khosla¹, R. Kumar¹
¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Minneapolis, MN, ³Hennepin County Medical Center, Minneapolis, MN
*Purpose: Living kidney donors were shown to have derangements of bone biomarkers resembling those occurring in early chronic kidney disease within 36 months of donation.…